OpGen Inc (OPGN, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. OpGen Inc is an precision medicine company using molecular diagnostics and bioinformatics to help combat infectious disease. OpGen Inc has a market cap of $12.630 million; its shares were traded at around $1.46 with and P/S ratio of 1.67.
For the last quarter OpGen Inc reported a revenue of $0.55 million, compared with the revenue of $0.75 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $2.95 million, a decrease of 8.3% from the previous year. For the last five years OpGen Inc had an average revenue growth rate of 1.4% a year.
The reported loss per diluted share was $2.22 for the year, compared with the loss per share of $30 in the previous year. The OpGen Inc had an operating margin of -447.39%, compared with the operating margin of -475.43% a year before. The 10-year historical median operating margin of OpGen Inc is -472.16%. The profitability rank of the company is 3 (out of 10).
At the end of the fiscal year, OpGen Inc has the cash and cash equivalents of $4.57 million, compared with $1.85 million in the previous year. The long term debt was $1.10 million, compared with $0.13 million in the previous year. OpGen Inc has a financial strength rank of 4 (out of 10).
At the current stock price of $1.46, OpGen Inc is traded at 59% discount to its historical median P/S valuation band of $3.56. The P/S ratio of the stock is 1.67, while the historical median P/S ratio is 4.04. The stock lost 33.92% during the past 12 months.
For the complete 20-year historical financial data of OPGN, click here.
